Application of 5,6,7,4'-tetrahydroxyflavone and its derivatives in the preparation of jak tyrosine protein kinase inhibitors
A technology of tyrosine protein and kinase inhibitors, which is applied in the application field of 5,6,7,4'-tetrahydroxyflavone and its derivatives in the preparation of JAK tyrosine protein kinase inhibitors, and can solve the problem of scutellarin Undiscovered problems, to achieve significant application value, strong affinity effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0049] Example 1 : Inhibitory effect of 5,6,7,4'-tetrahydroxyflavone and its derivatives on JAK enzyme
[0050] Enzyme selection model
[0051]Determination principle: The enzyme selection method is established according to the classic method reported by Abukhalaf et al. in 1993 (see Abukhalaf IK, et al (1993): Protein phosphatase assay using a modification of the P81paper protein kinase assay procedure. J Biochem Biophys Methods. 26:95-104). The principle of the experimental determination is: when there is ATP in the reaction system, JAK can transfer the γ phosphorus on the ATP to the specific tyrosine on the polypeptide substrate. Since part of the γ-phosphorus of ATP used in the reaction is labeled isotope 33, it can release β-rays. The intensity of γ-phosphorus incorporated into the polypeptide can be accurately measured by a liquid scintillation instrument, thereby determining the degree of phosphorylation of the substrate polypeptide molecule and the activity of tyro...
Embodiment 2
[0075] Example 2 : 5,6,7,4'-Tetrahydroxyflavone and its derivatives have half inhibitory doses of JAK3 and JAK2 (IC 50 ) determination
[0076] In order to accurately determine the inhibitory strength of 5,6,7,4'-tetrahydroxyflavone and its derivatives against JAK3 and JAK2 tyrosine protein kinases, half inhibitory dose (IC 50 ) enzymatic assay, see figure 2 and image 3 , and the ordinate is the percentage of inhibition of tyrosine kinase. The results showed that the 50% inhibitory doses of scutellarin and 5,6,7,4'-tetrahydroxyflavone and its derivatives against JAK3 tyrosine protein kinase were 6.9 micromoles and 3.0 micromoles respectively, while the reference substance The PFE 50% inhibitory dose was 19 micromolar. The 50% inhibitory doses of scutellarin and 5,6,7,4'-tetrahydroxyflavone and its derivatives against JAK2 tyrosine protein kinase are 57 micromoles and 4.2 micromoles respectively. Since scutellarin and 5,6,7,4'-tetrahydroxyflavone and its derivatives ha...
Embodiment 3
[0077] Example 3 : 5,6,7,4'-tetrahydroxyflavone and its derivatives cell assay process and results Cell model
[0078]Assay principle: Freshly prepared human peripheral blood lymphocytes were used as research objects in the experiment. Since peripheral blood lymphocytes are densely distributed with interleukin-2 receptors (IL2R), the activation of IL2R is mainly transmitted through the activation of JAK3. When IL2R is bound by interleukin-2 (IL-2), it immediately activates the associated JAK3, and JAK3 further activates STAT5 / STAT6. The activated further activated STAT5 / STAT6 is then transferred to the nucleus to initiate the expression of multiple target genes controlled by it. Interferon gamma (IFN gamma) is one of the controlled expression proteins, which is immediately secreted outside the lymphocytes once it is synthesized. By measuring the concentration of interferon gamma in the lymphocyte culture medium, the effect of drug molecules on cellular immune function can ...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com